Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | DAO | P14920 | 4/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | CES2 | O00748 | 1/20 | 0.38 |
| ▸ | CES1 | P23141 | 1/20 | 0.38 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.37 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.37 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.37 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 2/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2172166 | 0.80 | PIK3CA (0.45) | ALDH1A1DAOTSHRCNR2 | |
| SCHEMBL4771684 | 0.80 | PARP1 (0.40) | ALDH1A1MAOAMAOB | |
| SCHEMBL2432440 | 0.80 | KDM4E (0.45) | ALDH1A1MAOAMAOBTSHR | |
| SCHEMBL2370050 | 0.80 | DAO (0.45) | DAO | |
| SCHEMBL30260017 | 0.80 | KDM4E (0.45) | ALDH1A1MAOAMAOBTSHR | |
| SCHEMBL13224693 | 0.80 | KIF11 (0.30) | — | |
| SCHEMBL4767670 | 0.80 | CA6 (0.46) | ALDH1A1CNR1CNR2 | |
| SCHEMBL24410558 | 0.80 | ERN1 (0.35) | HTTALDH1A1L3MBTL1 | |
| SCHEMBL3414018 | 0.80 | ALDH1A1 (0.46) | ALDH1A1TSHR | |
| SCHEMBL2557796 | 0.80 | DAO (0.45) | ALDH1A1DAO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 96 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3723754-B1 | IMIDAZO [1,2-C] QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES | MERCK SHARP & DOHME LLC (US) | 2026-05-13 | — | — | EP | claimed |
| CN-120154006-A | Application of p-fluorobenzaldehyde and composition containing p-fluorobenzaldehyde in attracting cotton bollworms | 中国农业科学院植物保护研究所 | 2025-06-17 | — | — | CN | disclosed |
| US-20250129048-A1 | MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | PFIZER INC. (US) | 2025-04-24 | — | — | US | disclosed |
| WO-2024229221-A1 | ANDROGEN RECEPTOR MODULATORS AND METHODS FOR THEIR USE | CAPULUS THERAPEUTICS, LLC (US) | 2024-11-07 | — | — | WO | disclosed |
| EP-4452251-A1 | COMPOSITIONS AND METHODS OF USE TO TREAT 12-LIPOXYGENASE (12-LOX) MEDIATED DISEASES | Veralox Therapeutics Inc. (US) | 2024-10-30 | — | — | EP | disclosed |
| CN-116589454-A | Aromatic heterocyclic compound, preparation method and medical application thereof | 中国医药研究开发中心有限公司 | 2023-08-15 | — | — | CN | disclosed |
| WO-2023122494-A1 | COMPOSITIONS AND METHODS OF USE TO TREAT 12-LIPOXYGENASE (12-LOX) MEDIATED DISEASES | VERALOX THERAPEUTICS (US) | 2023-06-29 | — | — | WO | disclosed |
| EP-4097087-A1 | [(1,4,5-TRISUBSTITUTED-1H-PYRAZOL-3-YL)SULFANYL]ACETIC ACID DERIVATIVES, SALTS THEREOF, AND USE THEREOF AS HERBICIDAL INGREDIENTS | Bayer Aktiengesellschaft (DE) | 2022-12-07 | — | — | EP | disclosed |
| US-20220340893-A1 | BI-FUNCTIONAL COMPLEXES AND METHODS FOR MAKING AND USING SUCH COMPLEXES | NUEVOLUTION A/S (DK) | 2022-10-27 | — | — | US | disclosed |
| US-11319300-B2 | Polyfluoro-substituted aromatic heterocyclic derivative, pharmaceutical composition containing same, and applications thereof | GUANGZHOU LIXIN PHARMACEUTICAL CO., LTD. (CN) | 2022-05-03 | — | — | US | disclosed |
| US-6500503-B2 | Liquid crystal compound containing fluoro substituted benzene ring | CHISSO CORPORATION (JP) | 2002-12-31 | — | — | US | disclosed |
| US-20020103400-A1 | Process for producing optically active 1-(fluoro- or trifluoromethyl-substituted phenyl) ethylamine and process for purifying same | CENTRAL GLASS COMPANY, LIMITED (JP) | 2002-08-01 | — | — | US | disclosed |
| US-20020066888-A1 | Cyclohexane derivatives, liquid crystal compositions comprising the same and liquid crystal display devices | JNC PETROCHEMICAL CORPORATION (JP) | 2002-06-06 | — | — | US | disclosed |
| EP-1149885-A1 | Cyclohexane derivatives, liquid crystal compositions comprising the same and liquid crystal display devices | CHISSO CORPORATION (JP) | 2001-10-31 | — | — | EP | disclosed |
| US-5998415-A | Bicyclic heteroaryl-alkylene-(homo)piperazinones and thione analogues thereof, their preparation, and their use of as selective agonists of 5-HT1 -like receptors | MERCK SHARP & DOHME LTD. (GB) | 1999-12-07 | — | — | US | disclosed |
| US-5973156-A | Piperidine and tetrahydropyridine derivatives | MERCK SHARP & DOME LTD. (GB) | 1999-10-26 | — | — | US | disclosed |
| US-5889008-A | Substituted 1-indolylpropyl-4-phenethylpiperazadine derivatives | MERCK SHARP & DOHME, LTD. (GB) | 1999-03-30 | — | — | US | disclosed |
| EP-0861245-A1 | PIPERIDINE AND TETRAHYDROPYRIDINE DERIVATIVES | MERCK SHARP & DOHME LTD. (GB) | 1998-09-02 | — | — | EP | disclosed |
| WO-1997019073-A1 | PIPERIDINE AND TETRAHYDROPYRIDINE DERIVATIVES | MERCK SHARP & DOHME LIMITED (GB) | 1997-05-29 | — | — | WO | disclosed |
| WO-1997016446-A1 | BICYCLIC HETEROARYL-ALKYLENE-(HOMO)PIPERAZINONES AND THIONE ANALOGUES THEREOF, THEIR PREPARATION AND THEIR USE AS SELECTIVE AGONISTS OF 5-HT1-LIKE RECEPTORS | MERCK SHARP & DOHME LIMITED (GB) | 1997-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11319300-B2 | Polyfluoro-substituted aromatic heterocyclic derivative, pharmaceutical composition containing same, and applications thereof | AKT1, AKT2, AKT3 | HTT 1535/4885ALDH1A1 3227/4885DAO 1028/4885 |
| US-20020066888-A1 | Cyclohexane derivatives, liquid crystal compositions comprising the same and liquid crystal display devices | SCO2, KLK1, HCN2 | HTT 4568/4885ALDH1A1 2264/4885DAO 2027/4885 |
| US-20020103400-A1 | Process for producing optically active 1-(fluoro- or trifluoromethyl-substituted phenyl) ethylamine and process for purifying same | MAP2K5, MAP2K4, MAP2K1 | HTT 469/4885ALDH1A1 1280/4885DAO 352/4885 |
| US-20250129048-A1 | MELANOCORTIN 4 RECEPTOR ANTAGONISTS AND USES THEREOF | MC4R, MC3R, MC2R | HTT 1201/4885ALDH1A1 3955/4885DAO 2072/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.